Global Discovery Chemistry , Novartis Institutes for Biomedical Research , Basel 4002 , Switzerland.
Novartis Institutes for Biomedical Research , 5300 Chiron Way , Emeryville , California 94608 , United States.
J Med Chem. 2018 Nov 21;61(22):10155-10172. doi: 10.1021/acs.jmedchem.8b01318. Epub 2018 Oct 31.
SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), also known as Brahma homologue (BRM), is a Snf2-family DNA-dependent ATPase. BRM and its close homologue Brahma-related gene 1 (BRG1), also known as SMARCA4, are mutually exclusive ATPases of the large ATP-dependent SWI/SNF chromatin-remodeling complexes involved in transcriptional regulation of gene expression. No small molecules have been reported that modulate SWI/SNF chromatin-remodeling activity via inhibition of its ATPase activity, an important goal given the well-established dependence of BRG1-deficient cancers on BRM. Here, we describe allosteric dual BRM and BRG1 inhibitors that downregulate BRM-dependent gene expression and show antiproliferative activity in a BRG1-mutant-lung-tumor xenograft model upon oral administration. These compounds represent useful tools for understanding the functions of BRM in BRG1-loss-of-function settings and should enable probing the role of SWI/SNF functions more broadly in different cancer contexts and those of other diseases.
SWI/SNF 相关,基质相关,肌动蛋白依赖性染色质调节剂亚家族 A 成员 2(SMARCA2),也称为 Brama 同源物(BRM),是一种 Snf2 家族 DNA 依赖性 ATP 酶。BRM 及其密切同源物 Brama 相关基因 1(BRG1),也称为 SMARCA4,是相互排斥的 ATP 酶,属于大型 ATP 依赖性 SWI/SNF 染色质重塑复合物,参与基因表达的转录调控。目前尚未报道能够通过抑制其 ATP 酶活性来调节 SWI/SNF 染色质重塑活性的小分子,鉴于 BRG1 缺陷型癌症对 BRM 的依赖性已经得到充分证实,这是一个重要的目标。在这里,我们描述了变构双 BRM 和 BRG1 抑制剂,它们下调 BRM 依赖性基因表达,并在口服给药后在 BRG1 突变型肺肿瘤异种移植模型中显示出抗增殖活性。这些化合物是了解 BRM 在 BRG1 功能丧失背景下的功能的有用工具,并且应该能够更广泛地研究 SWI/SNF 功能在不同癌症环境和其他疾病中的作用。